This proposal is for a research contract to support in vitro investigations into the efficacy of GS967 on blocking persistent sodium current ('late lna') in two clinical conditions associated with human cardiac sodium channel gene (SCN5A) mutations; atrial fibrillation (AF) and long-QT syndrome (LQTS).
|Effective start/end date||3/1/14 → 2/29/16|
- Gilead Sciences, Inc. (Agmt 1/5/15)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.